Table 2 Laboratory parameters at start of RCA-CVVHD treatment and end of observation
|  | Normal liver function (bilirubin ≤2 mg/dl) | Mild liver failure (bilirubin 2–7 mg/dl) | Severe liver failure (bilirubin ≥7 mg/dl) | |||
|---|---|---|---|---|---|---|
Start | End | Start | End | Start | End | |
Number of patients | 48 | 43 | 42 | |||
Total bilirubin (mg/dl) | 0.8 ± 0.4 | 1.1 ± 0.8 | 3.6 ± 1.3 | 4.5 ± 3.2 | 18.4 ± 13.0 | 17.0 ± 11.2 |
Aspartate aminotransferase (U/L) | 193 ± 454 | 196 ± 414 | 716 ± 1864 | 636 ± 2021 | 391 ± 1206 | 391 ± 1336 |
Alanine aminotransferase (U/L) | 154 ± 602 | 104 ± 161 | 344 ± 766 | 361 ± 961 | 210 ± 476 | 199 ± 505 |
Creatinine (mg/dl) | 3.5 ± 1.5 | 1.4 ± 0.7 | 2.7 ± 1.4 | 1.4 ± 0.6 | 2.3 ± 1.1 | 1.6 ± 1.9 |
Urea (mg/dl) | 123 ± 75 | 53 ± 24 | 102 ± 59 | 49 ± 25 | 135 ± 69 | 74 ± 40 |
Sodium (mmol/L) | 141 ± 5 | 142 ± 4 | 140 ± 6 | 142 ± 4 | 140 ± 7 | 140 ± 4 |
Potassium (mmol/L) | 4.7 ± 0.7 | 4.3 ± 0.5 | 4.6 ± 0.8 | 4.4 ± 0.6 | 4.5 ± 0.7 | 4.3 ± 0.6 |
Phosphorus (mmol/L) | 1.8 ± 0.9 | 0.8 ± 0.3 | 1.7 ± 0.8 | 0.8 ± 0.4 | 1.5 ± 0.7 | 1.0 ± 0.5 |
Magnesium (mmol/L) | 1.1 ± 0.4 | 0.9 ± 0.1 | 1.0 ± 0.4 | 0.9 ± 0.2 | 1.0 ± 0.3 | 1.0 ± 0.2 |
Hematocrit (%) | 30 ± 4 | 31. ±4 | 29 ± 5 | 30 ± 6 | 28 ± 5 | 29 ± 4 |
Platelet count (count/nl) | 195 ± 170 | 159 ± 164 | 109 ± 85 | 92 ± 87 | 103 ± 91 | 98 ± 85 |
INR | 1.7 ± 1.0 | 1.4 ± 0.7 | 1.5 ± 0.3 | 1.4 ± 0.4 | 1.8 ± 0.7 | 1.7 ± 0.6 |
aPTT (s) | 52 ± 20 | 46 ± 10 | 50 ± 12 | 49 ± 17 | 59 ± 25 | 54 ± 16 |
Serum protein (g/dl) | 4.9 ± 1.1 | 5.2 ± 1.0 | 4.8 ± 1.1 | 5.0 ± 1.0 | 5.2 ± 1.1 | 5.3 ± 1.2 |
Serum albumin (g/dl) | 2.2 ± 0.6 | 2.2 ± 0.6 | 2.1 ± 0.6 | 2.3 ± 0.9 | 2.3 ± 0.6 | 2.3 ± 0.6 |
Total calcium (mmol/L) | 2.0 ± 0.3 | 2.1 ± 0.2 | 2.0 ± 0.4 | 2.3 ± 0.3 | 2.1 ± 0.3 | 2.3 ± 0.3 |
Ratio total/ionized Ca2+ | 1.8 ± 0.1 | 1.9 ± 0.1 | 1.8 ± 0.1 | 1.9 ± 0.2 | 1.8 ± 0.2 | 2.0 ± 0.3 |
Postfilter iCa (mmol/L) | 0.27 ± 0.05 | 0.28 ± 0.03 | 0.27 ± 0.06 | 0.29 ± 0.03 | 0.30 ± 0.03 | 0.30 ± 0.02 |